Ph.D., Vice President of Translational Medicine, OncoMed Pharmaceuticals
Ann Kapoun is Vice President of Translational Medicine at OncoMed Pharmaceuticals. Her expertise is in the clinical execution and implementation of biomarkers and patient stratification approaches. Dr. Kapoun served as Associate Director of Biomarker R&D in Clinical Pharmacology & Experimental Medicine at ALZA / Johnson & Johnson. Prior to that she was the Department Head of Biomarker R&D at Scios Inc., where she was responsible for their Biomarker and Pharmacogenomics programs in support of clinical trials. Dr. Kapoun received her Ph.D. from Indiana University, Bloomington, IN, and she has co-authored more than 30 scientific publications and patents.
Session: Cancer Diagnostics
In oncology, biomarkers have many applications, including risk assessment, screening, differential diagnosis, determination of prognosis, response to treatment, and monitoring progression of the cancer. In this session we will highlight the current state of predictive biomarkers for oncology including recent successes, lessons learned, and challenges to come. Among the topics to be discussed are novel clinical trial designs for personalized medicine, emerging predictive biomarkers in immune-oncology trials, lessons learned from PD-L1 as an as an immunotherapy biomarker, and the path forward for next generation sequencing in cancer diagnostics.